Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer
For resectable patient; surgery with Intraoperative Radiation Therapy (IORT). Radiation
Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within
12 weeks of surgery.
For marginally resectable patients; the patients will have 2-3 cycles of neoadjuvant
chemotherapy of FOLFIRINOX and then restaged, undergo surgery with IORT within 2-4 weeks
following chemotherapy. Then radiation therapy starting within 6-8 weeks. Followed by
FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Efficacy - Progression Free Survival
Interim analysis at specific time points. Measure disease response by CT scans per standard of care or when clinically indicated.
2 years after last patient enrolled
Theodore Pollock, DO
Southwestern Regional Medical Center, Inc.
United States: Food and Drug Administration
|Southwestern Regional Medical Center, Inc.||Tulsa, Oklahoma 74133|